F.-X. Lebas

889 total citations
9 papers, 227 citations indexed

About

F.-X. Lebas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, F.-X. Lebas has authored 9 papers receiving a total of 227 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Surgery. Recurrent topics in F.-X. Lebas's work include Lung Cancer Research Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). F.-X. Lebas is often cited by papers focused on Lung Cancer Research Studies (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). F.-X. Lebas collaborates with scholars based in France, French Polynesia and Réunion. F.-X. Lebas's co-authors include Mahmoud Zureik, F Blanchon, J. Piquet, Bernard Asselain, M Grivaux, B. Milleron, Marc Puyraveau, M. Mercier, D. Debieuvre and A Depierre and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer and The Lancet Oncology.

In The Last Decade

F.-X. Lebas

7 papers receiving 220 citations

Peers

Countries citing papers authored by F.-X. Lebas

Since Specialization

Citations

This map shows the geographic impact of F.-X. Lebas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F.-X. Lebas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F.-X. Lebas more than expected).

Fields of papers citing papers by F.-X. Lebas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F.-X. Lebas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F.-X. Lebas. The network helps show where F.-X. Lebas may publish in the future.

Co-authorship network of co-authors of F.-X. Lebas

This figure shows the co-authorship network connecting the top 25 collaborators of F.-X. Lebas. A scholar is included among the top collaborators of F.-X. Lebas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F.-X. Lebas. F.-X. Lebas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Caractéristiques et prise en charge des exacerbations aiguës de BPCO hospitalisées. Étude EABPCO–CPHG du Collège des pneumologues des hôpitaux généraux 2009 ·Revue des Maladies Respiratoires ·J. Piquet, J.-M. Chavaillon, P. David, Martin Fortin, Dominique L. Braun, (unknown), (unknown), (unknown), François Goupil, (unknown), C. Arvin-Berod, (unknown), F.-X. Lebas, (unknown), C. Dujon, M. Mornet, Nicolás Roche, Mahmoud Zureik, F Blanchon	10
2	Les pneumopathies par inhalation d'hydrocarbures 2008 ·Charles N. Haas, F.-X. Lebas, Claire Le Jeunne, W Lowenstein, Hervé Durand, (unknown)	0
3	4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index 2006 ·The Lancet Oncology ·F Blanchon, M Grivaux, Bernard Asselain, F.-X. Lebas, (unknown), J. Piquet, Mahmoud Zureik	92
4	Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer 2005 ·JNCI Journal of the National Cancer Institute ·(unknown), Élisabeth Quoix, Denis Moro‐Sibilot, M. Mercier, Jean-Luc Breton, D. Debieuvre, Patrick Richard, (unknown), B. Milleron, Dominique Herman, (unknown), F.-X. Lebas, Marc Puyraveau, A Depierre, (unknown)	105
5	The addition of cisplatin to cyclophosphamide‐doxorubicin‐etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma 1999 ·Cancer ·T. Urban, Claude Chastang, F.-X. Lebas, (unknown), (unknown), (unknown), J.-M. Bréchot, B Lebeau	3
6	1053 Phase III study of neo-adjuvant chemotherapy in resectable non-small cell lung cancer (NSCLC) 1995 ·European Journal of Cancer ·A Depierre, B. Milleron, D Moro, E. Quoix, B Lebeau, Cl. Chastang, Denis Braun, Henri Janicot, N. Paillot, S. Gouva, Bruno Coudert, Jean-Luc Breton, É. Lemarié, F.-X. Lebas, D. Coëtmeur, Luc Thiberville, J.-M. Bréchot	1
7	Cisplatin and vindesine for disseminated non-small cell lung cancer. Results of a prospective trial with 81 patients 1991 ·Lung Cancer ·J.M. Tourani, (unknown), I Caubarrère, (unknown), (unknown), (unknown), F.-X. Lebas, J.J. Lafitte, Jean‐Marie Andrieu	9
8	Two cycles of cisplatin-vindesine and radiotherapy for localized nonsmall cell carcinoma of the lung (stage III). Results of a prospective trial with 149 patients 1990 ·Cancer ·Jean‐Marc Tourani, Jean‐François Timsit, (unknown), (unknown), I Caubarrère, (unknown), (unknown), F.-X. Lebas, Jean‐Marie Andrieu	6
9	[Clear cell carcinoma of the thymus. Observation of a case of this exceptional variety of malignant thymoma]. 1987 ·PubMed ·(unknown), Anh Bui, François Eugène, F.-X. Lebas	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact